Trial reportOral diseases2026
Laser Acupuncture on the Management of Xerostomia in Sjögren's Disease: A Randomized Clinical Trial.
Trial report in Oral diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThis study evaluated the efficacy of photobiomodulation (PBM) at acupuncture points for managing xerostomia in patients with Sjögren's Disease. MATERIAL AND
methodsIn this randomized, double-blind clinical trial, 50 patients were assigned to PBM group (n = 22) or sham-PBM group (n = 28). The primary outcome was xerostomia symptoms assessed using a visual analogue scale (VAS). Secondary outcomes included Xerostomia Inventory, resting salivary flow rate (RSFR), and EULAR Sjögren's Syndrome Patient Reported Index score. Participants received weekly PBM sessions for four consecutive weeks, and evaluations were conducted at baseline, week 8 and 12.
resultsPBM showed a marginal tendency toward improvement on VAS (p = 0.0974) (OR = 1.929 95% CI 0.8939-4.525) and in the RSFR (p = 0.09996) (OR = +infinity 95% CI 0.9363-infinity) at week 8 compared with sham-PBM. However, no statistically significant differences were observed between groups at week 12 for any of the assessed outcomes.
conclusionPBM at acupuncture points demonstrated a slight short-term benefit at week 8 in improving xerostomia symptoms and RSFR, although these effects did not persist at 12 weeks. These preliminary results suggest a potential role for PBM at acupuncture points as a safe, noninvasive adjunctive therapy for xerostomia in patients with SjD, warranting further validation in larger, long-term trials.
trial registrationThis study was registered in The Brazilian Registry of Clinical Trials (U1111-1298-9891).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.